---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-004851"
form_type: "8-K"
ticker: "GLUE"
cik: "0001826457"
company_name: "Monte Rosa Therapeutics, Inc."
filed_at: "2022-03-29T23:59:59+00:00"
generated_at: "2026-06-26T15:09:39.495155+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Monte Rosa reports Q4 2021 net loss $23.4M; cash $351.4M; on track for MRT-2359 IND mid-2022

## Summary
- Net loss Q4 2021 $23.4M vs $19.7M in Q4 2020; FY 2021 loss $74.0M vs $35.9M in 2020.
- Cash, cash equivalents and restricted cash $351.4M as of Dec 31, 2021, expected runway into late 2024.
- R&D expenses Q4 2021 $18.1M, up from $9.9M in Q4 2020; G&A expenses $5.3M vs $2.1M.
- IND filing for MRT-2359 (GSPT1 degrader) targeted mid-2022; CDK2 and NEK7 programs in lead optimization.
- Promoted Jullian Jones to CBO and Phil Nickson to General Counsel; partnered with Weizmann Institute on covalent chemistry.

## SEC filing metadata
- accession: 0000950170-22-004851
- form_type: 8-K
- ticker: GLUE
- cik: 0001826457
- company_name: Monte Rosa Therapeutics, Inc.
- filed_at: 2022-03-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826457/000095017022004851/0000950170-22-004851-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826457/000095017022004851/glue-20220329.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-004851
- JSON: https://secwatch.observer/filing/0000950170-22-004851.json
- Plain text: https://secwatch.observer/filing/0000950170-22-004851.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.